Targanta Therapeutics Overview
- Founded
-
1997
- Status
-
Acquired/Merged
- Employees
-
113
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$42M
- Investors
-
1
Targanta Therapeutics General Information
Description
Developer of innovative antibiotics to treat serious infections in the hospital and other institutional settings. The company develops antibiotics for the treatment of serious gram-positive bacterial infections, including complicated skin and skin structure infections.
Contact Information
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Acquirer
Primary Office
- 222 Third Street
- Suite 2300
- Cambridge, MA 02142
- United States
+1 (514) 000-0000
Targanta Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 26-Feb-2009 | $42M | 00000 | 0000 | Completed | Clinical Trials - Phase 3 |
| 6. IPO | 10-Oct-2007 | 000.00 | 00000 | 00000 | Completed | Clinical Trials - Phase 3 |
| 5. Later Stage VC (Series C3) | 12-Feb-2007 | 000.00 | 00000 | 00000 | Completed | Generating Revenue |
| 4. Later Stage VC (Series C2) | 06-Jan-2005 | 0000 | 0000 | 000.00 | Completed | Generating Revenue |
| 3. Later Stage VC (Series C1) | 12-Mar-2002 | 000.00 | 0000 | 000.00 | Completed | Generating Revenue |
| 2. Early Stage VC (Series B) | 01-Dec-1999 | $28.7M | $30.3M | 000.00 | Completed | Product Development |
| 1. Seed Round | 01-Dec-1997 | $1.58M | $1.58M | 00.000 | Completed | Startup |
Targanta Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C3 | 0,000,000 | 00.000000 | 00 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
| Series C2 | 0,000,000 | 00.000000 | 00 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
| Series C1 | 0,000,000 | 00.000000 | 00 | 000.00 | 000.00 | 00 | 000.00 | 00.000 |
| Series B | 245,000 | $0.000100 | 8% | $199.5 | $199.5 | 1x | $199.5 | 1.35% |
| Series A | 20,000 | $0.000100 | $101.12 | $101.12 | 1x | $101.12 | 0.15% |
Targanta Therapeutics Executive Team (7)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Mark Leuchtenberger | President & Chief Executive Officer | ||
| Daniel Char | Vice President & General Counsel |
Targanta Therapeutics Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Randy Berholtz JD | Self | Board Member | 000 0000 |
Targanta Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Targanta Therapeutics Former Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Brookside Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Fonds de solidarité FTQ | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| GrowthWorks | Venture Capital | Minority | 000 0000 | 000000 0 | |
| InterMune | Corporation | 000 0000 | 000000 0 | ||
| Le Centre CDP Capital | Venture Capital | Minority | 000 0000 | 000000 0 |